Follow Roivant Sciences to never miss an important update.
The company reported a loss of 33 cents per share, which was slightly wider than the 30 cents analysts expected. Because the business is focused on developing new drugs rather than selling existing ones, it did not record any revenue for the quarter. This is normal for a biotech at this stage, as the real value lies in its pipeline of experimental therapies.
The most important news is that preparations to launch brepocitinib, a treatment for a rare inflammatory muscle disease, are on track for late September. This would mark a major shift for the company as it begins to generate its own product sales. Additionally, the company confirmed it received $950 million from Moderna in July as part of a patent settlement. This massive cash pile gives the company a long runway to fund its many drug trials without needing to borrow money or sell more stock.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The company has enrolled the first patients in a Phase 3 study, which is the final stage of testing required before a drug can be approved for sale. This trial is testing brepocitinib for cutaneous sarcoidosis, a condition that causes painful skin lumps and currently has no approved treatments.
While final results from this specific study are not expected until 2028, the start of the trial is a positive sign that the company is successfully moving its secondary programs forward. This drug has already received a Breakthrough Therapy designation from the FDA, a status meant to speed up the review of drugs that show early promise for serious conditions.
Source: GlobeNewsWire
The company has a choppy track record with more hits than misses lately. It suggests the business is still in a volatile stage where individual drug trial updates matter more than steady quarterly profits.
| Expectation | |
|---|---|
| EPS | $-0.35 |
| Revenue | $3M |
Follow Roivant Sciences to get the latest and most important updates.
Follow ROIV